Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease: Underuse of GLP-1RAs in patients with ASCVD

Scheen, André

doi:10.1016/j.deman.2024.100197

Article (Scientific journals)

Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease: Underuse of GLP-1RAs in patients with ASCVD

Scheen, André

2024 • In Diabetes Epidemiology and Management, 14, p. 100197

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/312611

DOI
10.1016/j.deman.2024.100197

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2024 paraoxical real-life underuse of GLP-1 receptor agonist.pdf

Author postprint (591.84 kB)

Creative Commons License - Attribution, Non-Commercial, No Derivative

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Cardiovascular disease; Clinical practice; GLP-1 receptor agonist; Meta-analysis; Real-life; Type 2 diabetes

Abstract :

[en] Introduction
[en] Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce the risk of cardiovascular (CV) complications in patients with type 2 diabetes (T2DM) and atherosclerotic cardiovascular disease (ASCVD) in placebo-controlled CV outcome trials, yet the use of these cardioprotective agents remains rather low in clinical practice.
[en] Methods
[en] Analysis of the proportion of T2DM patients treated with GLP-1RAs in retrospective observational studies by comparing patients with versus without established ASCVD.
[en] Results
[en] Nine cohorts from seven studies were collected in the international literature between 2019 and 2022. Overall, the percentages of patients treated with GLP-1RAs were low (< 10 %) in most studies, yet a progressive increase was noticed over time. The use of GLP-1RAs in patients with ASCVD was slightly lower in 7 out of 9 cohorts not higher when compared to the use in patients without ASCVD (odds ratio 0.80, 95 % CI 0.79–0.81).
[en] Conclusion
[en] Despite a positive trend over the last decade, the real-world use of GLP-1RAs remains limited, especially in patients with established ASCVD. Bridging the gap between clinical evidence of cardioprotective effects of GLP-1RAs and their underuse in clinical practice in T2DM patients at high/very high CV risk should be considered as a key objective for health care providers, especially cardiologists.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology
Cardiovascular & respiratory systems

Author, co-author :

Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques

Language :

English

Title :

Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease: Underuse of GLP-1RAs in patients with ASCVD

Publication date :

2024

Journal title :

Diabetes Epidemiology and Management

eISSN :

2666-9706

Volume :

Pages :

100197

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.sciencedirect.com/science/article/pii/S2666970624000027

Available on ORBi :

since 01 February 2024

Statistics

Number of views

9 (1 by ULiège)

Number of downloads

3 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

American diabetes association professional practice committee. 10. Cardiovascular disease and risk management: standards of care in diabetes-2024. Diabetes Care 47 (2024), S179–S218.
Scheen, A.J., Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol 16 (2020), 556–577.
Sattar, N., Lee, M.M.Y., Kristensen, S.L., Branch, K.R.H., Del Prato, S., Khurmi, N.S., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9 (2021), 653–662.
Marx, N., Husain, M., Lehrke, M., Verma, S., Sattar, N., GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation 146 (2022), 1882–1894.
Scheen, A.J., Cardiovascular outcome studies in type 2 diabetes : comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract 143 (2018), 88–100.
Ussher, J.R., Drucker, D.J., Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 20 (2023), 463–474.
Marx, N., Davies, M.J., Grant, P.J., Mathieu, C., Petrie, J.R., Cosentino, F., et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol 9 (2021), 46–52.
Davies, M.J., Aroda, V.R., Collins, B.S., Gabbay, R.A., Green, J., Maruthur, N.M., et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetologia 65 (2022), 1925–1966.
American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care, 47, 2024 S158-S78.
Scheen, A.J., Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation. Lancet Reg Health Eur, 29, 2023, 100627.
Scheen, A.J., Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?. Expert Rev Clin Pharmacol 16 (2023), 1053–1062.
Scheen, A.J., Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk. Diabetes Epidemiol Manag, 13, 2024, 100184.
Weng, W., Tian, Y., Kong, S.X., Ganguly, R., Hersloev, M., Brett, J., et al. The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States. Endocrinol Diabetes Metab, 2, 2019, e00076.
Farmer, R.E., Beard, I., Raza, S.I., Gollop, N.D., Patel, N., Tebboth, A., et al. Prescribing in type 2 diabetes patients with and without cardiovascular disease history: a descriptive analysis in the UK CPRD. Clin Ther 43 (2021), 320–335.
Shin, H., Schneeweiss, S., Glynn, R.J., Patorno, E., Trends in first-line glucose-lowering drug use in adults with type 2 diabetes in light of emerging evidence for SGLT-2i and GLP-1RA. Diabetes Care 44 (2021), 1774–1782.
Nargesi, A.A., Jeyashanmugaraja, G.P., Desai, N., Lipska, K., Krumholz, H., Khera, R., Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus. J Am Heart Assoc, 10, 2021, e021084.
Eberly, L.A., Yang, L., Essien, U.R., Eneanya, N.D., Julien, H.M., Luo, J., et al. Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum, 2, 2021, e214182.
Mosenzon, O., Alguwaihes, A., Leon, J.L.A., Bayram, F., Darmon, P., Davis, T.M.E., et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol, 20, 2021, 154.
Limonte, C.P., Hall, Y.N., Trikudanathan, S., Tuttle, K.R., Hirsch, I.B., de Boer, I.H., et al. Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. J Diabetes Complicat, 36, 2022, 108204.
Hao, R., Myroniuk, T., McGuckin, T., Manca, D., Campbell-Scherer, D., Lau, D., et al. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study. BMC Prim Care, 23, 2022, 124.
Khera, R., Dhingra, L.S., Aminorroaya, A., Li, K., Zhou, J.J., Arshad, F., et al. Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM. BMJ Med, 2, 2023, e000651.
Scheen, A.J., Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies. Diabetes Metab, 49, 2023, 101474.
McCoy, R.G., Van Houten, H.K., Deng, Y., Mandic, P.K., Ross, J.S., Montori, V.M., et al. Comparison of diabetes medications used by adults with commercial insurance vs medicare advantage, 2016 to 2019. JAMA Netw Open, 4, 2021, e2035792.
McCoy, R.G., Van Houten, H.K., Karaca-Mandic, P., Ross, J.S., Montori, V.M., Shah, N.D., Second-line therapy for type 2 diabetes management: the treatment/benefit paradox of cardiovascular and kidney comorbidities. Diabetes Care 44 (2021), 2302–2311.
Falkentoft, A.C., Andersen, J., Malik, M.E., Selmer, C., Gaede, P.H., Staehr, P.B., et al. Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study. Lancet Reg Health Eur, 14, 2022, 100308.
Arnold, S.V., Tang, F., Cooper, A., Chen, H., Gomes, M.B., Rathmann, W., et al. Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER. BMC Endocr Disord, 22, 2022, 111.
Lim, C.E., Pasternak, B., Eliasson, B., Danaei, G., Ueda, P., Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes. Eur J Prev Cardiol 30 (2023), 634–643.
Scheen, A.J., Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favourable benefit-safety profile. Expert Opin Drug Saf, 2024 Submitted (invited review).
Nelson, A.J., Pagidipati, N.J., Aroda, V.R., Cavender, M.A., Green, J.B., Lopes, R.D., et al. Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community. Circulation 144 (2021), 74–84.
Pagidipati, N.J., Nelson, A.J., Kaltenbach, L.A., Leyva, M., McGuire, D.K., Pop-Busui, R., et al. Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial. JAMA 329 (2023), 1261–1270.
Gunawan, F., Nassif, M.E., Partridge, C., Ahmad, T., Kosiborod, M., Inzucchi, S.E., Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications. Cardiovasc Endocrinol Metab 9 (2020), 56–59.
Vaduganathan, M., Patel, R.B., Singh, A., McCarthy, C.P., Qamar, A., Januzzi, J.L. Jr., et al. Prescription of glucagon-like peptide-1 receptor agonists by cardiologists. J Am Coll Cardiol 73 (2019), 1596–1598.
Honigberg, M.C., Chang, L.S., McGuire, D.K., Plutzky, J., Aroda, V.R., Vaduganathan, M., Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review. JAMA Cardiol 5 (2020), 1182–1190.
Marx, N., Federici, M., Schutt, K., Muller-Wieland, D., Ajjan, R.A., Antunes, M.J., et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44 (2023), 4043–4140.
Karagiannis, T., Bekiari, E., Tsapas, A., Socioeconomic aspects of incretin-based therapy. Diabetologia 66 (2023), 1859–1868.